Camonsertib is a Small molecule drug targeting ATR, at Phase 2. This 2026 report reviews clinical evidence, IP, deals, risks and a CONDITIONAL GO view.

Imlunestrant Tosylate is a Small molecule drug targeting ER, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.

Elacestrant hydrochloride is a Small molecule drug targeting ERα, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.

Repotrectinib is a Small molecule drug targeting ROS1 x TrkA x TrkB x TrkC, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks.

Futibatinib is a Small molecule drug targeting FGFR1 x FGFR2 x FGFR3 x FGFR4, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks.

Tozorakimab is a Monoclonal antibody targeting IL-33, at NDA/BLA. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.

Belapectin is a Polymer targeting galectin-3, at Phase 2. This 2026 report reviews clinical evidence, IP, deals, risks and a CONDITIONAL GO view.

Aldafermin: Discontinued. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.

Fordadistrogene movaparvovec is a AAV based gene therapy targeting DAG1, at Discontinued. This 2026 report reviews clinical evidence, IP, deals, risks.

Valoctocogene roxaparvovec: Phase 3. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.

Garadacimab-gxii is a Monoclonal antibody targeting Factor XIIa, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.

Clopidogrel napadisilate is a Small molecule drug targeting P2Y12 receptor, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks.